Interleukin-4 treatment reduces leukemia burden in acute myeloid leukemia

Keyphrases

• Interleukin-4 (IL-4) 100%
• Acute Myeloid Leukemia 100%
• Leukemia 100%
• Cyclopentenone 30%
• Peroxisome Proliferator-activated Receptor 20%
• Clinical Trials 10%
• Cell Culture 10%
• Potential Therapeutics 10%
• Intraperitoneal Injection 10%
• T Cells 10%
• Signaling Mechanism 10%
• Enhanced Expression 10%
• Murine Model 10%
• Allergy 10%
• Therapeutic Regimen 10%
• Endogenous Levels 10%
• Prostaglandin J2 10%
• Hematological Malignancies 10%
• Hematopoietic Stem Cells 10%
• Patient-derived 10%
• Beneficial Role 10%
• Prostaglandin D2 (PGD2) 10%
• P53-dependent Apoptosis 10%
• Therapeutic Role 10%
• Paracrine Signaling 10%
• Type 2 Immune Response 10%
• 14-prostaglandin J2 10%
• Endogenous Production 10%
• MLL-AF9 10%
• Acute Myeloid Leukemia Cells 10%
• Fusion Oncoprotein 10%
• Signature Cytokines 10%
• Autocrine Signaling 10%

Neuroscience

• Myeloid 100%
• Interleukin 4 100%
• Peroxisome Proliferator-Activated Receptor Gamma 20%
• Prostaglandin J2 20%
• In Vivo 10%
• P53 10%
• T Cell 10%
• Signaling Mechanism 10%
• Paracrine Signalling 10%
• Prostaglandin D2 10%
• Oncoprotein 10%
• Programmed Cell Death 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Peroxisome Proliferator Activated Receptor Gamma 10%
• 2 Chloro 5 Nitrobenzanilide 10%
• Peroxisome Proliferator Activated Receptor Gamma Antagonist 10%